NAD Boosters: Evidence Versus Marketing

If you take away one thing about NAD+ boosters, make it this: the human trials show that nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) do raise NAD+ in the blood, and they also show that nobody has yet demonstrated this makes a person live longer or age more slowly. The molecules reliably move a laboratory number. The promise printed on the bottle, that a higher number buys you healthier years, is the part the studies have not delivered.

Key points#

• NR and NMN consistently raise blood NAD+ in randomized human trials, often by a large margin.
• No controlled trial has shown either compound extends lifespan, prevents disease, or slows measurable aging in people.
• Short-term safety at studied doses looks acceptable, but the trials are small and last weeks to months.
• Whether an ingredient is sold as a supplement or studied as a drug reflects a regulatory pathway, not proof of benefit.

The idea that started it all#

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme that sits at the center of cellular housekeeping. Cells use it to turn food into usable energy, to help repair damaged DNA, and to run enzymes such as the sirtuins and PARPs that respond to cellular stress. In several species, tissue levels of NAD+ decline with age, and topping them back up corrects some age-related problems in laboratory animals. That is a real and reasonable line of inquiry, and it is why NR and NMN drew attention in the first place: both feed the salvage pathway that recycles NAD+ inside the cell.

The trouble is not the underlying biology. It is the size of the leap from an intriguing mechanism in mice to a confident claim about human aging. A hypothesis that deserves a serious trial is not the same thing as a conclusion, and most of what is sold today is priced as though the conclusion were already in.

What the human trials actually found#

Start with the pharmacology, because this is the part that holds up. In a randomized, double-blind, placebo-controlled crossover trial published in Nature Communications in 2018, Martens and colleagues gave 24 healthy adults aged 55 to 79 either 1000 mg of NR daily or a placebo for six weeks each. NR was well tolerated, and it raised NAD+ in blood cells by roughly 60 percent compared with placebo. As a demonstration that an oral precursor can lift the target molecule, this is clean and repeatable.

Now look at whether anything downstream changed. In the same study, the authors found no significant effect on exercise capacity, metabolic function, or motor performance. They noted a hint of lower blood pressure and arterial stiffness in the subgroup that started with elevated pressure, and they described it honestly as a signal worth testing in a larger trial, not a proven benefit.

NMN follows the same arc. A 2023 review in Advances in Nutrition by Song and colleagues gathered the published human NMN studies, which used daily doses from about 100 to 2000 mg in small groups of mostly older adults. NMN was generally safe and raised blood NAD+ by roughly 1.7 to 2.7 fold. The functional signals were modest and inconsistent: one group of women with prediabetes showed improved insulin sensitivity, but NAD+ did not always rise in skeletal muscle even when it climbed in blood. The reviewers' own bottom line is the fair summary of the whole field, that clear evidence for antiaging effects in humans is still scarce and it is too early to say these compounds will delay age-related decline.

Why a rising biomarker is not the finish line#

The outcomes that would justify a longevity claim are demanding ones: death, new disease, loss of strength or memory, disability. So far, no NAD+ precursor has been shown to change any of them in a controlled human trial. The available studies are small, run for a few weeks to a few months, and measure surrogates rather than the things patients actually care about.

Think of it as a car with a fuel gauge that has been reading empty. Adding fuel makes the needle move, and that is genuinely reassuring. It does not, by itself, tell you the car will now drive farther, faster, or for more years. A biomarker heading in the hoped-for direction is a reason to fund the long, larger trial. It is not a stand-in for having finished one. Sales copy tends to treat the moving needle as the destination.

Why two similar molecules sit in different legal boxes#

The regulatory history here is genuinely useful, and it is often misread. Under section 201(ff)(3)(B) of the Federal Food, Drug, and Cosmetic Act, an ingredient that has been approved as a new drug, or authorized for investigation as a new drug with substantial public clinical trials, is generally excluded from the definition of a dietary supplement, unless it was already sold as a supplement or food first. That one clause is why two chemically related molecules can end up in different legal categories.

NR came to market through the supplement and food routes. The FDA reviewed it through new dietary ingredient notifications and issued a "no questions" response to a generally recognized as safe (GRAS) notice for nicotinamide riboside chloride as a source of vitamin B3. NMN took a different route: it was authorized for investigation as a new drug, and in 2022 the FDA took the position that this history removed NMN from the supplement definition, a stance the agency later revised. For a reader, the lesson is what these labels do and do not mean. Being studied as an investigational drug is not evidence that a compound works, and being sold lawfully as a supplement is not evidence either. A legal category describes a pathway through the rules, not a proven effect on aging.

How to read a longevity supplement ad#

A few tells separate the science from the sales pitch. Watch for mouse or petri-dish data presented as if it were human proof. Watch for the jump from "raises NAD+" to "reverses aging." Watch for name-dropped enzymes and famous laboratories offered as if a mechanism were a result. A before-and-after biomarker chart shows that a product does what its chemistry predicts, which is a very different claim from showing it helped anyone. Consumer "biological age" tests deserve particular caution as marketing props; they are research tools with real measurement noise, not a personal verdict on your rate of aging.

The questions that cut through all of it are short. Is the endpoint a hard outcome or a surrogate? Was the study randomized and controlled, how many people took part, and for how long? Who paid for it? Ask those honestly and NR and NMN land exactly where the evidence puts them today: acceptable for short-term safety at studied doses, dependable at raising a biomarker, and unproven for the healthspan and longevity claims that sell them.